FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080589301> ?p ?o ?g. }

• W2080589301 endingPage "98" @default.
• W2080589301 startingPage "94" @default.
• W2080589301 abstract "TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) was a Phase 3, randomized, double blind, parallel-group, multinational head-to-head study of prasugrel vs. clopidogrel both on top of aspirin. The primary end point was the rate of cardiovascular death, nonfatal myocardial infarction (MI), or stroke, and was reached in 12.1% of patients treated with clopidogrel and in 9.9% of patients randomized to prasugrel, suggesting impressive vascular outcome benefit of prasugrel over clopidogrel. However, this overoptimistic interpretation of the trial results was challenged by the Food and Drug Administration (FDA) Secondary Review, which revealed several shortcomings with TRITON design and data interpretation including the front-loaded nature of prasugrel benefit. Recently, following approval with black box warning, the FDA posted the complete documentation set (Action Package), revealing additional information including the timing of loading in TRITON, and how it affects vascular outcomes. The detailed FDA communications revealed highly significant correlation of the loading dose delay and primary efficacy outcomes favoring prasugrel. Indeed, when patients in TRITON were loaded early, or pretreated, the benefit of prasugrel was nonexistent. However, the longer it takes during or especially after PCI to load with thienopyridine, the more prasugrel benefit occurs. Considering that pretreatment with clopidogrel was disallowed; that three quarters of patients in TRITON were loaded during or after intervention; and that prasugrel was used at the 60-mg loading dose, which is over three times more potent than 300 mg clopidogrel, the claim of superiority of prasugrel over clopidogrel is not valid due to inappropriate use of clopidogrel." @default.
• W2080589301 created "2016-06-24" @default.
• W2080589301 creator A5000582387 @default.
• W2080589301 date "2011-03-01" @default.
• W2080589301 modified "2023-10-18" @default.
• W2080589301 title "Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook" @default.
• W2080589301 cites W1456082183 @default.
• W2080589301 cites W1936929261 @default.
• W2080589301 cites W1980864734 @default.
• W2080589301 cites W2053379248 @default.
• W2080589301 cites W2079766569 @default.
• W2080589301 cites W2104549091 @default.
• W2080589301 cites W2119860290 @default.
• W2080589301 cites W2147746835 @default.
• W2080589301 cites W2156506897 @default.
• W2080589301 cites W2169387542 @default.
• W2080589301 cites W2598074109 @default.
• W2080589301 cites W2162886638 @default.
• W2080589301 doi "https://doi.org/10.1016/j.carrev.2010.01.008" @default.
• W2080589301 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21421187" @default.
• W2080589301 hasPublicationYear "2011" @default.
• W2080589301 type Work @default.
• W2080589301 sameAs 2080589301 @default.
• W2080589301 citedByCount "7" @default.
• W2080589301 countsByYear W20805893012012 @default.
• W2080589301 countsByYear W20805893012013 @default.
• W2080589301 countsByYear W20805893012014 @default.
• W2080589301 countsByYear W20805893012016 @default.
• W2080589301 countsByYear W20805893012017 @default.
• W2080589301 crossrefType "journal-article" @default.
• W2080589301 hasAuthorship W2080589301A5000582387 @default.
• W2080589301 hasConcept C126322002 @default.
• W2080589301 hasConcept C164705383 @default.
• W2080589301 hasConcept C168563851 @default.
• W2080589301 hasConcept C2777028646 @default.
• W2080589301 hasConcept C2777849778 @default.
• W2080589301 hasConcept C2779837110 @default.
• W2080589301 hasConcept C500558357 @default.
• W2080589301 hasConcept C71924100 @default.
• W2080589301 hasConceptScore W2080589301C126322002 @default.
• W2080589301 hasConceptScore W2080589301C164705383 @default.
• W2080589301 hasConceptScore W2080589301C168563851 @default.
• W2080589301 hasConceptScore W2080589301C2777028646 @default.
• W2080589301 hasConceptScore W2080589301C2777849778 @default.
• W2080589301 hasConceptScore W2080589301C2779837110 @default.
• W2080589301 hasConceptScore W2080589301C500558357 @default.
• W2080589301 hasConceptScore W2080589301C71924100 @default.
• W2080589301 hasIssue "2" @default.
• W2080589301 hasLocation W20805893011 @default.
• W2080589301 hasLocation W20805893012 @default.
• W2080589301 hasOpenAccess W2080589301 @default.
• W2080589301 hasPrimaryLocation W20805893011 @default.
• W2080589301 hasRelatedWork W1983666245 @default.
• W2080589301 hasRelatedWork W2031499028 @default.
• W2080589301 hasRelatedWork W2071646386 @default.
• W2080589301 hasRelatedWork W2084187773 @default.
• W2080589301 hasRelatedWork W2098152429 @default.
• W2080589301 hasRelatedWork W2127586058 @default.
• W2080589301 hasRelatedWork W2141069636 @default.
• W2080589301 hasRelatedWork W2369806290 @default.
• W2080589301 hasRelatedWork W3042915720 @default.
• W2080589301 hasRelatedWork W4311753511 @default.
• W2080589301 hasVolume "12" @default.
• W2080589301 isParatext "false" @default.
• W2080589301 isRetracted "false" @default.
• W2080589301 magId "2080589301" @default.
• W2080589301 workType "article" @default.